- Home
- BMBL vs DAWN Comparison
BMBL vs DAWN Comparison
Compare BMBL & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMBL
- DAWN
- Stock Information
- Founded
- BMBL 2014
- DAWN 2018
- Country
- BMBL United States
- DAWN United States
- Employees
- BMBL N/A
- DAWN N/A
- Industry
- BMBL Computer Software: Prepackaged Software
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- BMBL Technology
- DAWN Health Care
- Exchange
- BMBL Nasdaq
- DAWN Nasdaq
- Market Cap
- BMBL 661.5M
- DAWN 624.8M
- IPO Year
- BMBL 2021
- DAWN 2021
- Fundamental
- Price
- BMBL $5.83
- DAWN $7.29
- Analyst Decision
- BMBL Hold
- DAWN Strong Buy
- Analyst Count
- BMBL 13
- DAWN 7
- Target Price
- BMBL $6.50
- DAWN $27.86
- AVG Volume (30 Days)
- BMBL 2.9M
- DAWN 1.4M
- Earning Date
- BMBL 11-05-2025
- DAWN 10-29-2025
- Dividend Yield
- BMBL N/A
- DAWN N/A
- EPS Growth
- BMBL N/A
- DAWN N/A
- EPS
- BMBL N/A
- DAWN N/A
- Revenue
- BMBL $1,030,583,000.00
- DAWN $187,638,000.00
- Revenue This Year
- BMBL N/A
- DAWN $12.69
- Revenue Next Year
- BMBL N/A
- DAWN $48.51
- P/E Ratio
- BMBL N/A
- DAWN N/A
- Revenue Growth
- BMBL N/A
- DAWN 2190.50
- 52 Week Low
- BMBL $3.55
- DAWN $5.64
- 52 Week High
- BMBL $9.22
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- BMBL 32.11
- DAWN 51.50
- Support Level
- BMBL $5.75
- DAWN $6.70
- Resistance Level
- BMBL $7.32
- DAWN $8.28
- Average True Range (ATR)
- BMBL 0.28
- DAWN 0.36
- MACD
- BMBL -0.09
- DAWN 0.04
- Stochastic Oscillator
- BMBL 5.10
- DAWN 32.82
About BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.